Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000621503 | SCV000739934 | likely pathogenic | Cardiovascular phenotype | 2016-03-23 | criteria provided, single submitter | clinical testing | The c.3491-2A>C intronic variant results from an A to C substitution two nucleotides upstream from coding exon 32 in the MYBPC3 gene. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6133 samples (12266 alleles) with coverage at this position. This nucleotide position is highly conserved conserved in available vertebrate species. Using the ESEfinder splice site prediction tool, this alteration is predicted to abolish the native splice acceptor site; however, direct evidence is unavailable. Alterations that disrupt the canonical splice acceptor site are typically deleterious in nature (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). As such, the c.3491-2A>C variant is classified as likely pathogenic. |